BioStem Technologies, Inc. (OTC PINK: BSEM) a leading life sciences company specializing in the development and sale of perinatal tissue-based allografts for use in regenerative therapies, today announced that its subsidiary, BioStem Life Sciences has been awarded the prestigious accolade of accreditation by the American Association of Tissue Banks® (AATB®). BioStem Life Sciences is now accredited for Donor Eligibility Assessment, Processing, Storage, and Distribution of Birth Tissue and Cellular Tissue for Transplantation. [Read more…]
Cellenkos’ Cord Blood T-Regulatory Cells Show Promise in COVID-19 Induced ARDS
HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]
B-MoGen Biotechnologies, a Bio-Techne Company, Announces Opening of 2 Class 7 Clean Suites for Cellular Therapy Manufacturing
Contract Development & Manufacturing (CDMO):Â
B-MoGen’s ISO 7 cleanrooms now open for business
B-MoGen Biotechnologies, a unit of Bio-Techne, is proud to announce new cGMP cellular therapy manufacturing capacity for Phase I and Phase II clinical trials.
Luminary Therapeutics and Case Western Reserve University Enter Formal Collaboration for Development of BAFF CAR
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020–Â Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs. [Read more…]
AASCP to Host 1st Virtual Board Certification Ceremony for Stem Cell Physicians
The American Academy of Stem Cell Physicians (AAOSCP) will create history on August 2, 2020, by hosting the first virtual Board Certification for Stem Cell Physicians.
On August 2-4, 2019, the American Academy of Stem Cell Physicians hosted a Scientific Congress at the Hyatt Regency in Miami, Florida. The highly anticipated event featured three days of educational and events with leading physicians and pioneers from across the fields of stem cell, live cell and regenerative medicine.
During this event, the AASCP Scientific Congress offered the first Board Certifications to eligible stem cell physicians. A challenging three-hour written examination for Board Certification was conducted, creating a pathway for Diplomat and Fellowship Certification in Regenerative Medicine (RM).
This year, the AASCP’s Congress will be delivered over August 1-2, 2020, and will include the first Virtual Board Certification for Stem Cell Physicians. [Read more…]
- « Previous Page
- 1
- …
- 183
- 184
- 185
- 186
- 187
- …
- 334
- Next Page »